Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 9143
Country/Region: Kenya
Year: 2016
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $2,079,400 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $366,943
Care: Orphans and Vulnerable Children (HKID) $12,952
Care: TB/HIV (HVTB) $79,660
Care: Pediatric Care and Support (PDCS) $71,902
Strategic Information (HVSI) $210,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $27,000
Testing: HIV Testing and Counseling (HVCT) $75,967
Sexual Prevention: Other Sexual Prevention (HVOP) $562,174
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $46,718
Treatment: Adult Treatment (HTXS) $595,619
Treatment: Pediatric Treatment (PDTX) $30,465
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,647
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 2,870
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 15,584
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 12,650
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 32,751
HTS_TST Service Delivery Point (Facility): Inpatient 2017 3,506
HTS_TST Service Delivery Point (Facility): Outpatient 2017 9,607
HTS_TST Service Delivery Point (Facility): Pediatric 2017 3,632
HTS_TST Service Delivery Point (Facility): PMTCT 2017 3,176
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 334
HTS_TST Service Delivery Point (Facility): VCT 2017 11,267
HTS_TST Service Delivery Point (Facility): VMMC 2017 1,229
HTS_TST Sum of Aggregated Age/Sex <15 2017 4,517
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 28,234
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 32,751
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 58
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 55
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 413
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 353
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 133
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 163
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 296
PMTCT_ART Already on ART at beginning of current pregnancy 2017 68
PMTCT_ART New on ART 2017 36
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,249
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 55
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 49
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 2
PMTCT_EID Sum of Infant Age disaggregates 2017 104
PMTCT_STAT By: Known positives at entry 2017 71
PMTCT_STAT By: Number of new positives identified 2017 38
PMTCT_STAT Number of new ANC and L&D clients 2017 3,420
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 3,249
PMTCT_STAT Sum of Positives Status disaggregates 2017 109
PP_PREV Aggregated Age/sex: <15 Female 2017 4,602
PP_PREV Aggregated Age/sex: <15 Male 2017 4,602
PP_PREV Aggregated Age/sex: 15+ Female 2017 18,673
PP_PREV Aggregated Age/sex: 15+ Male 2017 18,923
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 46,800
PP_PREV Total number of people in the target population 2017 150,000
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 28
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 49
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 81
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 81
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 733
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 367
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 733
TB_SCREENDX Screen Result: Screened Positive for TB 2017 815
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 1,953
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 1,891
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 103
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 130
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 4,077
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 51
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 8
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 109
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 172
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 172
TX_CURR Aggregated Age/Sex: <15 Female 2017 99
TX_CURR Aggregated Age/Sex: <15 Male 2017 127
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,708
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,788
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 3,722
TX_CURR Sum of Aggregated Age/Sex <15 2017 226
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 3,496
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 3,722
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 30
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 30
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 350
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 230
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 640
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 640
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 3,720
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 3,348
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 90
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 62
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 1,741
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 1,455
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 105
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 125
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 1,729
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,761
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 28
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 28
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 333
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 219
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 608
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 640
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 30
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 30
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 350
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 230
VMMC_CIRC By Age: 0-60 days 2017 10
VMMC_CIRC By Age: 10-14 2017 320
VMMC_CIRC By Age: 15-19 2017 35
VMMC_CIRC By Age: 20-24 2017 35
VMMC_CIRC By Age: 25-29 2017 35
VMMC_CIRC By Age: 30-49 2017 65
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 500
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 500
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 490
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 390
Cross Cutting Budget Categories and Known Amounts Total: $116,184
Food and Nutrition: Commodities $60,890
Gender: Gender Based Violence (GBV) $20,000
GBV Prevention
Implementation
Capacity building
Renovation $35,294